Startup OncoDxRx harnesses the power of proprietary liquid biopsy technologies for better clinical diagnostics and therapeutics

OncoDxRx is a pioneer, innovator and leader in liquid biopsy-based molecular diagnostics and well positioned for this revolution. The portfolios installed are among the most unique and best-performing in the molecular diagnostic industry, such as the PGA and MRD (minimal residual disease) assays, multi-cancer early detection (MCED) tests as well as DNA repair activity measurement which all benefit from exclusive cell-free DNA/mRNA knowhow and trade secret. OncoDxRx will thus secure its forefront position to deal with cancer patients in all stages, whether in the context of cancer screening and prevention or in the context of treatment selection, recurrence monitoring or drug discovery.

With OncoDxRx's proprietary, one-of-a-kind and transformative technologies, combined with its exclusive knowhow and trade secret, the company offers a menu of innovative blood-based tests that enable cancer patients to begin personalized treatment earlier than ever before. It's the ONLY company that can provide a portfolio of fit-for-purpose and competition-free assays using ONE simple tube of blood. Unlike other "Liquid Biopsy" diagnostics on the market, OncoDxRx's trade secrets will guarantee technological barriers that no one will cross, differentiating itself from competitors and securing a top-notch and unchallengeable position in this industry.

“The significance of this fact is that every assay we developed is one-of-its-kind and fulfilling unmet clinical needs with tremendous market potential. These unique assays require only single tubes of blood, no need for huge capital investment, easy for training and implementation in a regular laboratory, i.e., laboratory ready.” The company added.